NOAC (rivaroxaban) vs vitamin K antagonist (VKA)
Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
NOAC (rivaroxaban) probably leads to higher strokea compared with standard‐dose VKA (moderate certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyRR 14.13 [1.87, 106.81]3 studies · 425 participantsModerate